Among these, SRPX2 plays a role in invasive properties of BE-GICs, raising the possibility that SRPX2 could be further explored as a potential therapeutic target for glioblastoma with a hypo-methylation bias and ACS enrichment. This evidence concerns the gene SRPX2 and glioblastoma.